NEW YORK — A private equity consortium comprising Warburg Pincus and Advent International is in advanced talks to acquire medical device maker Baxter International Inc’s biopharma solutions business in a deal that could reach or exceed $4 billion, people familiar with the matter said on Sunday.
Warburg Pincus and Advent have submitted the most attractive offer to Baxter in an auction that drew interest from other private equity firms as well as major players in the biomedical sector such as Thermo Fisher Scientific Inc, the sources said.
Advertisement 2
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Unlimited online access to articles from across Canada with one account.
- Get exclusive access to the National Post ePaper, an electronic replica of the print edition that you can share, download and comment on.
- Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
- Support local journalists and the next generation of journalists.
- Daily puzzles including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles by Kevin Carmichael, Victoria Wells, Jake Edmiston, Gabriel Friedman and others.
- Daily content from Financial Times, the world’s leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
Financial Post Top Stories
Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.
By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
The buyout consortium has turned to other private equity firms to help fund the deal as direct lenders, one of the sources added.
There is no certainty that Warburg Pincus and Advent will successfully complete negotiations to acquire the unit and Baxter may still opt to sell to another bidder or keep the business, according to the sources. They requested anonymity because details of the sale process are confidential.
Baxter, Warburg and Advent did not immediately respond to requests for comment. Thermo Fisher declined to comment.
Baxter’s biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.
Advertisement 3
Baxter, which has a market value of $23 billion, said in January it would explore a sale of the unit to “enhance focus and improve capital structure,” a reference to its push to shed non-core businesses and pay down some of its $16.4 billion debt pile.
Baxter also plans to spin off its renal care and acute therapies units. The company said dialysis operations, which are a part of Baxter’s renal care unit, had become a drag on its margin.
Medtronic Plc, another medical device maker, unveiled a plan in October to spin off its patient monitoring and respiratory interventions businesses, which have since attracted interest from potential buyers. (Reporting by David Carnevali and Anirban Sen in New York; editing by Diane Craft and Sandra Maler)
